Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Leads Emerging Nations in Pharma M&A

publication date: Dec 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Drug companies are increasing their M&A spending in emerging markets, and China is garnering the lion’s share of activity, according to data from Thomson Reuters. All together, including capital from both overseas and domestic drug manufacturers, M&A in emerging countries has totaled $20 billion this year. That’s a jump of 67% over last year. China deals were responsible for one-third of the total: $6.8 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors